The stock of BioNexus Gene Lab Corp. (NASDAQ:BGLC) increased by $0.12 on Friday to finish at $1.30, up 10.17 percent. The last five days have seen an average of 9,664,600 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$10.1000. The average number of shares traded over the last 20 days was 5,904,430, while the average volume over the last 50 days totaled 3,134,272.
BGLC stock dropped -38.97% since last month. On 08/16/23, the company’s shares reached a one-month low of $0.6505. The stock touched a high of $17.88 on 07/12/23, after rallying from a low of $0.65 in 52 weeks. The price of BGLC stock has declined by -88.60% or -$10.1000 this year, reaching a new high 3 times. Still, the stock price is down -92.73% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Beta for the stock is 0.81. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.21, the price-to-book (PB) ratio of 3.17, and the price-to-cash flow ratio of 38.35.
Financial Health
For the recent quarter, BioNexus Gene Lab Corp.’s quick ratio was 2.20, while its current ratio was 2.80, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 13.00% percent. BioNexus Gene Lab Corp.’s EBITDA margin for the recent year was -3.34%, whereas its operating margin stood at -4.70% for the same period.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BGLC’s return on assets (ROA) during the last 12 months has been -6.90%. There was a -5.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -8.80%.
Earnings Surprise
Net income for the quarter came in at $2.57 million, while revenues rose by 3.11% to $2.38 million. At the end of BioNexus Gene Lab Corp.’s most recent quarter, its total debt was $45760.0.
Technical Picture
Here’s a quick look at BioNexus Gene Lab Corp.’s (BGLC) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 43.41%, suggesting the stock is Neutral, with a 379.26% historical volatility rate.
The stochastic %K and %D were 52.49% and 51.00% respectively, while the average true range (ATR) was 0.6414. Based on the 14-day stochastic reading of 48.86%, the RSI (14) reading is 42.14%. On the 9-day MACD Oscillator, the stock is at 0.2500, and the 14-day reading is at 0.2570.
Analyst Ratings
Analysts have assigned BioNexus Gene Lab Corp. (BGLC) an – rating. BGLC is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
